Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma

Genes Chromosomes and Cancer

Volumn 51, Issue 2, 2012, Pages 111-126

  Negri, Tiziana ^a   Brich, Silvia ^a   Conca, Elena ^a   Bozzi, Fabio ^a   Orsenigo, Marta ^a   Stacchiotti, Silvia ^a   Alberghini, Marco ^b   Mauro, Valentina ^a   Gronchi, Alessandro ^a   Dusio, Giuseppina F ^c   Pelosi, Giuseppe ^a   Picci, Piero ^b   Casali, Paolo G ^a   Pierotti, Marco A ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CHROMOSOME 22; CHROMOSOME 8; CHROMOSOME ABERRATION; CLEAR CELL SARCOMA; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CALMODULIN-BINDING PROTEINS; CHROMOSOME DUPLICATION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GENE EXPRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RNA-BINDING PROTEINS; SARCOMA, CLEAR CELL; SEQUENCE ANALYSIS, DNA; TRISOMY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83055186555     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20933     Document Type: Article

References (55)

1. Angeloni D, Danilkovitch-Miagkova A, Ivanova T, Braga E, Zabarovsky E, Lerman MI. 2007. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene 26: 4499-4512.
2. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. 2003. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: A sensitive and specific immunohistochemical assay. Am J Surg Pathol 27: 750-761.
3. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR, Weiss SW. 2010. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol 34: 1395-1406.
4. Bardella C, Costa B, Maggiora P, Patane' S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF. 2004. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 64: 5154-5161.
5. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, Winckler W, Fisher DE, Getz G, Meyerson M, Jaffe DB, Gabriel SB, Lander ES, Dummer R, Gnirke A, Nusbaum C, Garraway LA. 2010. Integrative analysis of the melanoma transcriptome. Genome Res 20: 413-427.
6. Bloethner S, Scherer D, Drechsel M, Hemminki K, Kumar R. Malignant melanoma-A genetic overview. 2009. Acta Dermosifiliogr 100 ( Suppl 1): 38-51.
7. Chung EB, Enzinger FM. 1983. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol 7: 405-413.
8. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE. 2006. Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. Cancer Cell 9: 473-484.
9. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. 2010. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 70: 639-645.
10. Dunham C, Hussong J, Seiff M, Pfeifer J, Perry A. 2008. Primary intracerebral angiomatoid fibrous histiocytoma: Report of a case with a t(12;22)(q13;q12) causing type 1 fusion of the EWS and ATF-1 genes. Am J Surg Pathol 32: 478-484.
11. Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K. 2009. RON receptor tyrosine kinase in human gliomas: Expression, function, and identification of a novel soluble splice variant. J Neurochem 109: 969-980.
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
13. Enzinger FM. 1965. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer 18: 1163-1174.
14. Ferrari A, Casanova M, Bisogno G, Mattke A, Meazza C, Gandola L, Sotti G, Cecchetto G, Harms D, Koscielniak E, Treuner J, Carli M. 2002. Clear cell sarcoma of tendons and aponeuroses in pediatric patients: A report from the Italian and German soft tissue sarcoma cooperative group. Cancer 15: 3269-3276.
15. Finley JW, Hanypsiak B, McGrath B, Kraybill W, Gibbs JF. 2001. Clear cell sarcoma: The Roswell Park experience. J Surg Oncol 77: 16-20.
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
17. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122.
18. Gerber DE, Minna JD. 2010. ALK inhibition for non-small cell lung cancer: From discovery to therapy in record time. Cancer Cell 18: 548-551.
19. Hantschke M, Mentzel T, Rütten A, Palmedo G, Calonje E, Lazar AJ, Kutzner H. 2010. Cutaneous clear cell sarcoma: A clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol 34: 216-222.
20. Hellyer NJ, Cheng K, Koland JG. 1998. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 333: 757-763.
21. Hisaoka M, Ishida T, Kuo TT, Matsuyama A, Imamura T, Nishida K, Kuroda H, Inayama Y, Oshiro H, Kobayashi H, Nakajima T, Fukuda T, Ae K, Hashimoto H. 2008. Clear cell sarcoma of soft tissue: A clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol 32: 452-460.
22. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. 2009. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 4: e5717.
23. Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E. 2009. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells. Kidney Int 75: 1173-1183.
24. Kuphal S, Bosserhoff A. 2009. Recent progress in understanding the pathology of malignant melanoma. J Pathol 219: 400-409.
25. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PH, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P, Bridge J. 2001. The der(17)t(X ;17)(p11 ;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20: 48-57.
26. Leonis MA, Thobe MN, Waltz SE. 2007. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol 3: 441-448.
27. Limon J, Debiec-Rychter M, Nedoszytko B, Liberski PP, Babińska M, Szadowska A. 1994. Aberration of chromosome 22 and polysomy of chromosome 8 as non-random changes in clear cell sarcoma. Cancer Genet Cytogenet 72: 141-145.
28. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. 2009. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 69: 6871-6878.
29. Lu Y, Yao HP, Wang MH. 2007. Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164.
30. Mascarenhas JB, Littlejohn EL, Wolsky RJ, Young KP, Nelson M, Salgia R, Lang D. 2010. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23: 225-237.
31. Miettinen M. 2010. Neuroectodermal tumors: Melanocytic, glial, and meningeal neoplasms. In: Miettinen M, editor. Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions, 1st ed. Cambridge University Press, pp. 724-754.
32. Panagopoulos I, Mertens F, Isaksson M, Mandahl N. 2005. Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet Cytogenet 156: 74-76.
33. Patel RM, Downs-Kelly E, Weiss SW, Folpe AL, Tubbs RR, Tuthill RJ, Goldblum JR, Skacel M. 2005. Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol 18: 1585-1590.
34. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S. 2006. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12: 6643-6651; Erratum in: Clin Cancer Res 2007; 13: 4313.
35. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S. 2009. PDGFRA, PDGFRB, EGFR, and downstream signalling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 11: 725-736.
36. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. 2007. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13: 2246-2253.
37. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A. 2008. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197.
38. Righi A, Dimosthenous K, Rosai J. 2008. PEComa: Another member of the MiT tumor family? Int J Surg Pathol 16: 16-20.
39. Ross H, Argani P. 2010. Xp11 translocation renal cell carcinoma. Pathology 42: 369-373.
40. Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, Eisenacher M, Voss R, Van Valen F, Baer C, Selle B, Spahn L, Liao SK, Lee KA, Hogendoorn PC, Reifenberger G, Gabbert HE, Poremba C. 2004. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res 64: 3395-3405.
41. Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S, Schneider DT, Kuhnen C, Vollmann A, Brockhoff G, Gabbert HE, Poremba C. 2006. Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. Neoplasia 8: 613-622.
42. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A, Henley B, Hunt JT, Jeyaseelan R, Kamath A, Kim K, Lippy J, Lombardo LJ, Manne V, Oppenheimer S, Sack JS, Schmidt RJ, Shen G, Stefanski K, Tokarski JS, Trainor GL, Wautlet BS, Wei D, Williams DK, Zhang Y, Zhang Y, Fargnoli J, Borzilleri RM. 2009. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 52: 1251-1254.
43. Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, Busam K, Gallardo H, DeSantis D, Brennan MF, Cordon-Cardo C, Wolchok JD, Houghton AN. 2003. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol 21: 1775-1781.
44. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. 2010. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107: 7692-7697.
45. Song JS, Choi J, Kim JH, Jang SJ, Cho KJ. 2010. Diagnostic utility of EWS break-apart fluorescence in situ hybridization in distinguishing between non-cutaneous melanoma and clear cell sarcoma. Pathol Int 60: 608-613.
46. Stacchiotti S. 2010. Clear cell sarcoma (CCS): Clinical behaviour and response to chemotherapy. J Clin Oncol 28: 15s.
47. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. 2009. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 15: 1096-1104.
48. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. 2010. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol 21: 1130-1131.
49. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S. 2010. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol 12: 776-789.
50. Tanaka M, Kato K, Gomi K, Matsumoto M, Kudo H, Shinkai M, Ohama Y, Kigasawa H, Tanaka Y. 2009. Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 33: 1416-1420.
51. Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Laé M, Fisher DE, Ladanyi M. 2007. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67: 919-929.
52. Wang MH, Yao HP, Zhou YQ. 2006. Oncogenesis of RON receptor tyrosine kinase: A molecular target for malignant epithelial cancers. Acta Pharmacol Sin 27: 641-650.
53. Weiss SW, Goldblum JR. 2008. Enzinger and Weiss's Soft Tissue Tumors, 5th ed. Mosby: St. Louis, pp. 926-934.
54. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. 2007. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67: 4408-4417.
55. Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, Speleman F, Fletchers CD, Aurias A, Thomas G. 1993. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet 4: 341-345.